Human iPSC-derived hepatocytes for drug discovery, translational research and toxicity testing

Presented as part of NC3Rs NAMs Technology Partn3Ring webinar series, this short pitch, delivered by Dr Tom Harris-Brown, showcases bit.bio’s ioHepatocytes, a scalable source of human iPSC-derived hepatocytes engineered to enable the industrialisation of New Approach Methodologies (NAMs).

Tailored for researchers and industry professionals advancing 3Rs replacement technologies for drug toxicity assessment, the presentation explains how these cells provide a standardised foundation for highly predictive toxicology and disease modelling.

This talk provides a concise overview of opti-ox™ technology alongside a clear call for partnership, as bit.bio actively seeks collaborators to integrate these next-generation systems into advanced 2D/3D assays and complex microphysiological systems.